about
Synthesis, Structural Analysis, and Biological Evaluation of Thioxoquinazoline Derivatives as Phosphodiesterase 7 InhibitorsInhibition of glioblastoma growth by the thiadiazolidinone compound TDZD-8CCAAT/enhancer-binding protein beta plays a regulatory role in differentiation and apoptosis of neuroblastoma cellsPhosphodiesterase 7 inhibition preserves dopaminergic neurons in cellular and rodent models of Parkinson diseaseNovel N-Acetyl Bioisosteres of Melatonin: Melatonergic Receptor Pharmacology, Physicochemical Studies, and Phenotypic Assessment of Their Neurogenic Potential.The alkaloids of Banisteriopsis caapi, the plant source of the Amazonian hallucinogen Ayahuasca, stimulate adult neurogenesis in vitro.Role of C/EBPβ transcription factor in adult hippocampal neurogenesis.Neuroprotective efficacy of quinazoline type phosphodiesterase 7 inhibitors in cellular cultures and experimental stroke model.Glycogen synthase kinase-3 inhibitors as potent therapeutic agents for the treatment of Parkinson diseaseNew melatonin-N,N-dibenzyl(N-methyl)amine hybrids: potent neurogenic agents with antioxidant, cholinergic, and neuroprotective properties as innovative drugs for Alzheimer's disease.Phosphodiesterase 7 inhibition induces dopaminergic neurogenesis in hemiparkinsonian rats.PDE7 inhibitor TC3.6 ameliorates symptomatology in a model of primary progressive multiple sclerosisGlycogen synthase kinase 3 inhibition promotes adult hippocampal neurogenesis in vitro and in vivo.Complement component 3 (C3) expression in the hippocampus after excitotoxic injury: role of C/EBPβ.Crosstalk between phosphodiesterase 7 and glycogen synthase kinase-3: two relevant therapeutic targets for neurological disorders.Subtly Modulating Glycogen Synthase Kinase 3 β: Allosteric Inhibitor Development and Their Potential for the Treatment of Chronic Diseases.Pharmacological tools based on imidazole scaffold proved the utility of PDE10A inhibitors for Parkinson's disease.New cinnamic - N-benzylpiperidine and cinnamic - N,N-dibenzyl(N-methyl)amine hybrids as Alzheimer-directed multitarget drugs with antioxidant, cholinergic, neuroprotective and neurogenic properties.New neurogenic lipoic-based hybrids as innovative Alzheimer's drugs with σ-1 agonism and β-secretase inhibition.CCAAT/enhancer binding protein β directly regulates the expression of the complement component 3 gene in neural cells: implications for the pro-inflammatory effects of this transcription factor.The CB1 receptor is required for the establishment of the hyperlocomotor phenotype in developmentally-induced hypothyroidism in mice.Decreased CCAAT/enhancer binding protein β expression inhibits the growth of glioblastoma cells.15-Deoxi-Delta(12,14)-prostaglandin J2 is a tubulin-binding agent that destabilizes microtubules and induces mitotic arrest.The spot 14 protein inhibits growth and induces differentiation and cell death of human MCF-7 breast cancer cells.Regulation of inflammatory response in neural cells in vitro by thiadiazolidinones derivatives through peroxisome proliferator-activated receptor gamma activation.15-deoxy-Delta-12,14-prostaglandin J2 induces programmed cell death of breast cancer cells by a pleiotropic mechanism.Normal level of thyroglobulin messenger ribonucleic acid in a human congenital goiter with thyroglobulin deficiency.Silencing phosphodiesterase 7B gene by lentiviral-shRNA interference attenuates neurodegeneration and motor deficits in hemiparkinsonian mice.Is a gene for microcephaly located on chromosome 1?Developmentally-induced hypothyroidism alters the expression of Egr-1 and Arc genes and the sensitivity to cannabinoid agonists in the hippocampus. Possible implications for memory and learning.CCAAT/Enhancer binding protein β silencing mitigates glial activation and neurodegeneration in a rat model of Parkinson's diseaseDevelopmental hypothyroidism increases the expression of kainate receptors in the hippocampus and the sensitivity to kainic acid-induced seizures in the rat.Thyroid hormone regulates oxidative phosphorylation in the cerebral cortex and striatum of neonatal rats.Enhancement of BRCA1 gene expression by the peroxisome proliferator-activated receptor gamma in the MCF-7 breast cancer cell line.New insights into the effects of extra nucleolus organizer regions.The mitochondrial respiratory complex I is a target for 15-deoxy-delta12,14-prostaglandin J2 action.Thyroid hormone regulates Galphai1 gene expression in the rat cerebellar cortex during post-natal development.Anticonvulsant and neuroprotective effects of the novel calcium antagonist NP04634 on kainic acid-induced seizures in rats.Hypothyroidism decreases the biogenesis in free mitochondria and neuronal oxygen consumption in the cerebral cortex of developing rats.CCAAT/enhancer binding protein beta deficiency provides cerebral protection following excitotoxic injury.
P50
Q27654567-F7E7AB95-90CA-4DE3-BB3B-F115371E0EDAQ28476019-3ED39952-1E1A-4AB2-9371-E413CEECB449Q28512299-A52284D5-99DC-446D-9230-088ADE5A8F9CQ28742424-E2629D59-E988-4EED-9E8F-A11DC9BA4AA6Q30961259-D2BA1AFA-E2B7-4AA9-AFCA-5871107E8054Q33902992-AAC5AF13-08AD-4E7D-8AE9-98FBCE306798Q34049241-F788E15A-F4C2-4924-9032-C8148F79B2E0Q34234232-5D161915-58D6-499B-A271-1BDFEDEBB471Q34591684-62905821-FB16-4691-BFA0-10F6EF7BC3B9Q35150027-CC4302E3-F746-4D04-B4AF-EBA7529AD6EBQ35665339-8F1E5A95-C8F0-49EF-8F3A-FAE64619A044Q36016406-71DD22B9-CB95-4092-9D0F-49E84DE30067Q36415259-6134EC15-975C-4018-ACAA-66388D6CBEEBQ37356880-8817159D-E072-4736-AD28-CD861587B66EQ37657490-5C0C26F2-CB2C-439E-882B-4FFB8373CA59Q38678504-F9EBB65A-0281-4E1F-AA59-461EFC495207Q38686069-410083EC-0A49-49BE-B2CE-42B8E96BD976Q38766306-7571CD1D-EE2D-443F-85CD-470243BBE661Q38842928-EBB4B3E6-E7B0-4A81-9F01-39F9168B3A3DQ38916940-2EEC79F9-5158-4B3F-9703-5D004C01757CQ39065504-028D5ED4-18F3-44E0-9E34-8FDBAFF5B1ACQ39615781-0498F4AA-4F9C-4B5D-B256-18A68A335CEEQ39829642-229FB423-665F-4E12-8291-AB7BDDB1D3A4Q40437082-4F9C4200-C156-495A-8CDF-861EDB09F4B8Q40437395-DC8767F5-9B94-4B7A-B72E-78D0AB286AEDQ40504054-BFEB6A9D-6899-496C-88A2-F18CF02E6751Q41472489-CC441367-7073-4853-BB67-B8D8B9DE5AB3Q41745623-7A86E606-9793-4CAC-BDEB-3963191A393CQ41934601-5AC9DB8F-CD1A-481F-82E0-1739DAAC7B4CQ42514431-B06F5A1F-53C9-4408-82CE-ED2F63BDA157Q42670542-798F71A4-EF5E-499A-8848-18D70D21060AQ43089883-66DA3F11-5519-4E1D-AD51-C2CD1F149121Q43735204-0F597A09-358B-4C7B-8E1B-BC4AFEDBAE52Q44559508-BB7C2880-F508-420D-8C8A-0F880D4A55B5Q45101075-2FD30B5A-E7A4-45E1-92F3-D8279C5DB799Q45226885-27A4FAC6-DD88-4BD8-9405-098FC5125010Q45233018-00DC7441-5CD3-4AA7-B156-F3F56FF8B5FBQ45946742-F0D7773D-AD28-4151-87C7-84695C2517E9Q46038811-CC503368-A725-4D69-8471-FBF695263079Q46664679-41E5B5F7-B2E8-4F84-B629-A9997CBE68CB
P50
description
hulumtuese
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Ana Perez-Castillo
@ast
Ana Perez-Castillo
@en
Ana Perez-Castillo
@es
Ana Perez-Castillo
@nl
type
label
Ana Perez-Castillo
@ast
Ana Perez-Castillo
@en
Ana Perez-Castillo
@es
Ana Perez-Castillo
@nl
prefLabel
Ana Perez-Castillo
@ast
Ana Perez-Castillo
@en
Ana Perez-Castillo
@es
Ana Perez-Castillo
@nl
P106
P1153
7005466124
P21
P31
P4012
P496
0000-0002-2632-5853